Cargando…

Histone deacetylase 6 in cancer

Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone subst...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Zhang, Chao, Hassan, Shafat, Liu, Xinyue, Song, Fengju, Chen, Kexin, Zhang, Wei, Yang, Jilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122547/
https://www.ncbi.nlm.nih.gov/pubmed/30176876
http://dx.doi.org/10.1186/s13045-018-0654-9
_version_ 1783352676694622208
author Li, Ting
Zhang, Chao
Hassan, Shafat
Liu, Xinyue
Song, Fengju
Chen, Kexin
Zhang, Wei
Yang, Jilong
author_facet Li, Ting
Zhang, Chao
Hassan, Shafat
Liu, Xinyue
Song, Fengju
Chen, Kexin
Zhang, Wei
Yang, Jilong
author_sort Li, Ting
collection PubMed
description Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. Furthermore, HDAC6 also upregulates several critical factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy. Several selective HDAC6 inhibitors are currently in clinical trials for cancer treatment and bring hope for patients with malignant tumors. A fuller understanding of HDAC6 as a critical regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies. Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.
format Online
Article
Text
id pubmed-6122547
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61225472018-09-05 Histone deacetylase 6 in cancer Li, Ting Zhang, Chao Hassan, Shafat Liu, Xinyue Song, Fengju Chen, Kexin Zhang, Wei Yang, Jilong J Hematol Oncol Review Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. Furthermore, HDAC6 also upregulates several critical factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy. Several selective HDAC6 inhibitors are currently in clinical trials for cancer treatment and bring hope for patients with malignant tumors. A fuller understanding of HDAC6 as a critical regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies. Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target. BioMed Central 2018-09-03 /pmc/articles/PMC6122547/ /pubmed/30176876 http://dx.doi.org/10.1186/s13045-018-0654-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Li, Ting
Zhang, Chao
Hassan, Shafat
Liu, Xinyue
Song, Fengju
Chen, Kexin
Zhang, Wei
Yang, Jilong
Histone deacetylase 6 in cancer
title Histone deacetylase 6 in cancer
title_full Histone deacetylase 6 in cancer
title_fullStr Histone deacetylase 6 in cancer
title_full_unstemmed Histone deacetylase 6 in cancer
title_short Histone deacetylase 6 in cancer
title_sort histone deacetylase 6 in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122547/
https://www.ncbi.nlm.nih.gov/pubmed/30176876
http://dx.doi.org/10.1186/s13045-018-0654-9
work_keys_str_mv AT liting histonedeacetylase6incancer
AT zhangchao histonedeacetylase6incancer
AT hassanshafat histonedeacetylase6incancer
AT liuxinyue histonedeacetylase6incancer
AT songfengju histonedeacetylase6incancer
AT chenkexin histonedeacetylase6incancer
AT zhangwei histonedeacetylase6incancer
AT yangjilong histonedeacetylase6incancer